AimedBio and Boehringer Ingelheim Begin Phase I Study of BI 4060107
The first patient has been dosed in the first-in-human study of the antibody-drug conjugate in people with advanced solid tumors.
The first patient has been dosed in the first-in-human study of the antibody-drug conjugate in people with advanced solid tumors.